ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
How to run a coronavirus vaccine trial in a global pandemic
An interview with ICON’s Nuala Murphy, President, Clinical Research Services, on ‘How to run a coronavirus vaccine trial in a global pandemic.’ Dr. Murphy discusses ICON’s experience with the Pfizer/BioNTech COVID-19 vaccine, the world’s first COVID-19 vaccine to achieve Emergency Use Authorisation.
Pharma’s digital transformation – How to best incorporate wearables amid an evolving landscape
A thought leadership piece which examines how disruptions from COVID-19 have forced sponsors, clinicians and regulators to embrace digital's full potential to keep clinical trials moving forward.
Pfizer COVID vaccine trial proved remote monitoring, other innovations work, ICON CEO says
ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post- pandemic.
Advancing digital endpoints in clinical trials
Marie McCarthy and Manpreet Sidhu discuss some of the challenges associated with the widespread adoption of digital health technology, the data that can be leveraged from wearables, and where advances are being made.
Life Sciences special feature
ICON recently contributed to the Irish Times' Life Sciences special feature with expert commentary from Dr. Nuala Murphy, President of Clinical Research Services, a case study with CFO Brendan Brennan, and a report on career opportunities for clinical researchers with a job profile of Rory Considine, Clinical Operations Manager.
Rediscovering HIV: A new decade of research and innovation on the horizon
In this Pharmafile article, Dr. Caroline Forkin and Shelley McLendon discuss a new decade of research and innovation on the horizon for HIV.
UK regulator defends rapid approval of vaccine after Fauci criticism
ICON’s Dr. Andrew Garrett, Executive Vice President Scientific Operations, comments on MHRA, the UK regulator, following their emergency use authorisation of the Pfizer COVID-19 vaccine.
Decentralised & hybrid trials: The future of clinical trials post pandemic
An interview with EB McLindon on why the future of drug development involves decentralising parts of the clinical trial process.
New whitepaper details challenges and explores solutions to end AIDS epidemic
This article reports on ICON's new whitepaper "The evolution of HIV treatments: From PrEP to vaccines, where we are today and what’s next".
Moving from "on-site" to agile: The changing dynamic in study management
Pharmafocus features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.